Purwanto Ibnu, Heriyanto Didik Setyo, Ghozali Ahmad, Widodo Irianiwati, Dwiprahasto Iwan, Aryandono Teguh, Haryana Sofia Mubarika
Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.
Department of Anatomical Pathology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University/Dr. Sardjito Hospital, Yogyakarta, Indonesia.
World J Oncol. 2020 Oct;11(5):216-222. doi: 10.14740/wjon1302. Epub 2020 Oct 15.
Triple negative breast cancer (TNBC) (represents roughly 25% of all breast cancers in Yogyakarta) still has the worst survival compared to other breast cancer subtypes. Results from recent studies have shown that inhibition of programmed death-ligand 1 receptor (PD-L1) in TNBC patients is associated with better prognosis. Currently, data on PD-L1 expression and its prognostic value in Indonesian TNBC patients are still relatively unknown. This study aimed to investigate the expression of PD-L1 in Indonesian TNBC patients as preliminary proof to support PD-L1 inhibitor as a possible treatment option near in the future.
We retrospectively included stage I-III TNBC patients diagnosed between 2014 and 2017 in Dr. Sardjito Hospital, Yogyakarta, Indonesia. Clinical variables were collected from medical record. Paraffin blocks of biopsy specimen were retrieved to examine mRNA level of PD-L1.
We included 48 subjects with mean age of 51.09 years and mean body mass index (BMI) of 24.58. The 3-year overall survival (OS) was 58.3%. Overexpression of PD-L1 mRNA in TNBC patients is associated with worse prognosis (P < 0.01). There were no statistically significant associations between PD-L1 mRNA expression and any of the clinicopathologic variables examined.
In summary, PD-L1 mRNA overexpression is associated with worse survival in Indonesian TNBC patients, independent of other established risk factors. PD-L1 mRNA is expressed in all of our samples, presenting as a feasible alternative or complementary method in deciding which patient might benefit from receiving PD-L1 inhibitor.
三阴性乳腺癌（TNBC）（在日惹所有乳腺癌中约占25%）与其他乳腺癌亚型相比，生存率仍然最差。最近的研究结果表明，TNBC患者中程序性死亡配体1受体（PD-L1）的抑制与更好的预后相关。目前，关于印度尼西亚TNBC患者中PD-L1表达及其预后价值的数据仍然相对较少。本研究旨在调查印度尼西亚TNBC患者中PD-L1的表达情况，作为支持PD-L1抑制剂在不久的将来成为一种可能治疗选择的初步证据。
我们回顾性纳入了2014年至2017年期间在印度尼西亚日惹萨迪托博士医院诊断为I-III期TNBC的患者。从病历中收集临床变量。检索活检标本的石蜡块以检测PD-L1的mRNA水平。
我们纳入了48名受试者，平均年龄为51.09岁，平均体重指数（BMI）为24.58。3年总生存率（OS）为58.3%。TNBC患者中PD-L1 mRNA的过表达与较差的预后相关（P<0.01）。PD-L1 mRNA表达与所检查的任何临床病理变量之间均无统计学显著关联。
总之，PD-L1 mRNA过表达与印度尼西亚TNBC患者较差的生存率相关，独立于其他已确定的危险因素。PD-L1 mRNA在我们所有的样本中均有表达，在决定哪些患者可能从接受PD-L1抑制剂中获益方面，是一种可行的替代或补充方法。
